Article

NDA accepted for kidney cancer agent

AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.

Related Videos
2 experts in this video
2 experts in this video
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.